Zactima News and Research

RSS
Zactima is a substance being studied in the treatment of lung cancer and other types of cancer. It may block the growth and spread of tumor cells and prevent the growth of new blood vessels that tumors need to grow. Zactima is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called vandetanib.
Research on rare cancers

Research on rare cancers

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Targeted therapy based on molecular signatures for treating lung cancer

Targeted therapy based on molecular signatures for treating lung cancer

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

New cancer drugs boost drug spending

New cancer drugs boost drug spending

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

NewYork-Presbyterian and AstraZeneca collaborate in series of cancer studies

NewYork-Presbyterian and AstraZeneca collaborate in series of cancer studies